Ranolazine improves endothelial function in patients with stable coronary artery disease
Authors:
- Snehal R. PatelSPSnehal R. Patel
- Elsa PinassiEPElsa Pinassi
- Catalin MindrescuCMCatalin Mindrescu
- Eileen V. HermanceEHEileen V. Hermance
- Michael N. InfantinoMIMichael N. Infantino
- John T. CoppolaJCJohn T. Coppola
- Cezar S. StaniloaeCSCezar S. Staniloae
- 1 August 2009
- journal article
- research article
- Published by Wolters Kluwer Health in Coronary Artery Disease
- Vol. 20 (5) , 343-347
Abstract
We investigated the effect of ranolazine on endothelial-dependent vasodilatation (EDV), serum markers of endothelial dysfunction, and inflammation. Endothelial dysfunction has been shown to be independently associated with the occurrence of cardiovascular events. We sought to investigate whether ranolazine, a novel antianginal medication with no effect on heart rate or blood pressure, improves endothelial function in patients with stable coronary artery disease (CAD). Twenty-seven patients with stable CAD were randomly assigned to either 1000 mg twice daily of ranolazine or to matching placebo for 6 weeks and then crossed over for an additional 6 weeks in a double-blind design. EDV was assessed using reactive hyperemia peripheral arterial tonometry (RH-PAT) at baseline, 6, and 12 weeks. Markers of endothelial dysfunction and inflammation were also evaluated. After 6 weeks, treatment with ranolazine significantly increased the EDV RH-PAT index as compared with baseline (1.85+/-0.42 vs. 2.08+/-0.57, P = 0.037). EDV RH-PAT did not change while on placebo (1.69+/-0.35 vs. 1.78+/-0.41, P = 0.29). In addition, there was a significant drop in asymmetric dimethylarginine levels with ranolazine treatment (0.66+/-0.12 vs. 0.60+/-0.11 micromol/l, P = 0.02) and a near significant decrease in C-reactive protein levels (0.40+/-0.80 vs. 0.30+/-0.61 mg/dl, P = 0.05). Ranolazine improves endothelial function, asymmetric dimethylarginine, and C-reactive protein levels in a group of patients with stable CAD. Our results suggest a novel mechanism of action of ranolazine.Keywords
This publication has 25 references indexed in Scilit:
- Inhibition of late (sustained/ persistent) sodium current: a potential drug target to reduce intracellular sodium-dependent calcium overload and its detrimental effects on cardiomyocyte functionEuropean Heart Journal Supplements, 2004
- Electrophysiological Effects of Ranolazine, a Novel Antianginal Agent With Antiarrhythmic PropertiesCirculation, 2004
- Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe anginaJACC, 2004
- Effects of Ranolazine With Atenolol, Amlodipine, or Diltiazem on Exercise Tolerance and Angina Frequency in Patients With Severe Chronic AnginaA Randomized Controlled TrialJAMA, 2004
- Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failureJournal of Cardiac Failure, 2002
- Short-Term Treatment With Ranolazine Improves Mechanical Efficiency in Dogs With Chronic Heart FailureCirculation Research, 2002
- Prognostic Impact of Coronary Vasodilator Dysfunction on Adverse Long-Term Outcome of Coronary Heart DiseaseCirculation, 2000
- Long-Term Follow-Up of Patients With Mild Coronary Artery Disease and Endothelial DysfunctionCirculation, 2000
- Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heartCardiovascular Research, 1994
- Paradoxical Vasoconstriction Induced by Acetylcholine in Atherosclerotic Coronary ArteriesNew England Journal of Medicine, 1986